The present invention relates to combination therapies employing tumor targeted bispecific OX40 antibodies, in particular anti-FAP/anti-OX40 antibodies in combination with T-cell activating anti-CD3 bispecific antibodies specific for a tumor-associated antigen, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
